190 related articles for article (PubMed ID: 30300042)
1. Upfront HIPEC and bevacizumab-containing adjuvant chemotherapy in advanced epithelial ovarian cancer.
Paris I; Cianci S; Vizzielli G; Fagotti A; Ferrandina G; Gueli Alletti S; Costantini B; Cosentino F; Capoluongo E; Pasqualoni M; Scambia G
Int J Hyperthermia; 2018; 35(1):370-374. PubMed ID: 30300042
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer.
Garcia Garcia Y; de Juan Ferré A; Mendiola C; Barretina-Ginesta MP; Gaba Garcia L; Santaballa Bertrán A; Bover Barcelo I; Gil-Martin M; Manzano A; Rubio Pérez MJ; Romeo Marin M; Arqueros Núñez C; García-Martínez E; Gonzalez Martin A
Int J Gynecol Cancer; 2019 Jul; 29(6):1050-1056. PubMed ID: 31263024
[TBL] [Abstract][Full Text] [Related]
3. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial.
Deraco M; Kusamura S; Virzì S; Puccio F; Macrì A; Famulari C; Solazzo M; Bonomi S; Iusco DR; Baratti D
Gynecol Oncol; 2011 Aug; 122(2):215-20. PubMed ID: 21665254
[TBL] [Abstract][Full Text] [Related]
4. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: upfront therapy, at first recurrence, or later?
Gonzalez Bayon L; Steiner MA; Vasquez Jimenez W; Asencio JM; Alvarez de Sierra P; Atahualpa Arenas F; Rodriguez del Campo J; Garcia Sabrido JL
Eur J Surg Oncol; 2013 Oct; 39(10):1109-15. PubMed ID: 23870278
[TBL] [Abstract][Full Text] [Related]
5. Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer.
Gouy S; Ferron G; Glehen O; Bayar A; Marchal F; Pomel C; Quenet F; Bereder JM; Le Deley MC; Morice P
Gynecol Oncol; 2016 Aug; 142(2):237-42. PubMed ID: 27246305
[TBL] [Abstract][Full Text] [Related]
6. Minimally invasive secondary cytoreduction plus HIPEC versus open surgery plus HIPEC in isolated relapse from ovarian cancer: a retrospective cohort study on perioperative outcomes.
Fagotti A; Costantini B; Gallotta V; Cianci S; Ronsini C; Petrillo M; Pacciani M; Scambia G; Fanfani F
J Minim Invasive Gynecol; 2015; 22(3):428-32. PubMed ID: 25461683
[TBL] [Abstract][Full Text] [Related]
7. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
[TBL] [Abstract][Full Text] [Related]
8. Interval Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in First-Line Treatment for Advanced Ovarian Carcinoma: A Feasibility Study.
D'Hondt V; Goffin F; Roca L; Dresse D; Leroy C; Kerger J; Cordier L; de Forges H; Veys I; Liberale G
Int J Gynecol Cancer; 2016 Jun; 26(5):912-7. PubMed ID: 27051055
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.
Ansaloni L; Agnoletti V; Amadori A; Catena F; Cavaliere D; Coccolini F; De Iaco P; Di Battista M; Framarini M; Gazzotti F; Ghermandi C; Kopf B; Saponara M; Tauceri F; Vallicelli C; Verdecchia GM; Pinna AD
Int J Gynecol Cancer; 2012 Jun; 22(5):778-85. PubMed ID: 22572845
[TBL] [Abstract][Full Text] [Related]
10. The role of cytoreductive surgery and HIPEC in epithelial ovarian cancer.
Halkia E; Spiliotis J
J BUON; 2015 May; 20 Suppl 1():S12-28. PubMed ID: 26051328
[TBL] [Abstract][Full Text] [Related]
11. Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series.
Fagotti A; Petrillo M; Costantini B; Fanfani F; Gallotta V; Chiantera V; Turco LC; Bottoni C; Scambia G
Gynecol Oncol; 2014 Feb; 132(2):303-6. PubMed ID: 24378877
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy.
Lim SL; Havrilesky LJ; Habib AS; Secord AA
Gynecol Oncol; 2019 May; 153(2):376-380. PubMed ID: 30718126
[TBL] [Abstract][Full Text] [Related]
13. [Management of epithelial ovarian cancer. Short text drafted from the French joint recommendations of FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa].
Lavoue V; Huchon C; Akladios C; Alfonsi P; Bakrin N; Ballester M; Bendifallah S; Bolze PA; Bonnet F; Bourgin C; Chabbert-Buffet N; Collinet P; Courbiere B; De la Motte Rouge T; Devouassoux-Shisheboran M; Falandry C; Ferron G; Fournier L; Gladieff L; Golfier F; Gouy S; Guyon F; Lambaudie E; Leary A; Lecuru F; Lefrere-Belda MA; Leblanc E; Lemoine A; Narducci F; Ouldamer L; Pautier P; Planchamp F; Pouget N; Ray-Coquard I; Rousset-Jablonski C; Senechal-Davin C; Touboul C; Thomassin-Naggara I; Uzan C; You B; Daraï E
Bull Cancer; 2019 Apr; 106(4):354-370. PubMed ID: 30850152
[TBL] [Abstract][Full Text] [Related]
14. Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer.
Carrabin N; Mithieux F; Meeus P; Trédan O; Guastalla JP; Bachelot T; Labidi SI; Treilleux I; Rivoire M; Ray-Coquard I
Bull Cancer; 2010 Apr; 97(4):E23-32. PubMed ID: 20202920
[TBL] [Abstract][Full Text] [Related]
15. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
Zivanovic O; Abramian A; Kullmann M; Fuhrmann C; Coch C; Hoeller T; Ruehs H; Keyver-Paik MD; Rudlowski C; Weber S; Kiefer N; Poelcher ML; Thiesler T; Rostamzadeh B; Mallmann M; Schaefer N; Permantier M; Latten S; Kalff J; Thomale J; Jaehde U; Kuhn WC
Int J Cancer; 2015 Feb; 136(3):699-708. PubMed ID: 24895230
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P
Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812
[TBL] [Abstract][Full Text] [Related]
17. Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases.
Di Giorgio A; De Iaco P; De Simone M; Garofalo A; Scambia G; Pinna AD; Verdecchia GM; Ansaloni L; Macrì A; Cappellini P; Ceriani V; Giorda G; Biacchi D; Vaira M; Valle M; Sammartino P
Ann Surg Oncol; 2017 Apr; 24(4):914-922. PubMed ID: 27896512
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy before definite operative approach for women with advanced-stage epithelial ovarian cancer.
Wang PH
Taiwan J Obstet Gynecol; 2018 Oct; 57(5):623-624. PubMed ID: 30342639
[No Abstract] [Full Text] [Related]
19. A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer.
Chiva LM; Gonzalez-Martin A
Gynecol Oncol; 2015 Jan; 136(1):130-5. PubMed ID: 25434634
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin.
Eveno C; Passot G; Goéré D; Soyer P; Gayat E; Glehen O; Elias D; Pocard M
Ann Surg Oncol; 2014 Jun; 21(6):1792-800. PubMed ID: 24337648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
